ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.- Spearheaded the development and deployment of machine learning models to predict molecular properties from compound structure to aid in identification and optimization of novel drugs.- Designed and led implementation of cloud-based ETL pipelines to streamline ingestion of experimental results into machine learning models.- Developed standardized tooling designed to accelerate model training and evaluation.- Analyzed key experimental and model results to advance drug discovery programs.

Enterprise Machine Learning Tools Team- Led implementation of extensible generalized linear model components for out-of-memory data in Python and Dask.- Developed framework for rapid prototyping of feature selection algorithms.- Refactored CI/CD pipelines for internal modeling libraries to enhance security and improve performance.- Consulted with data science teams to improve scalability of modeling pipelines.- Presented at company-wide data science conference on best practices for collaboration between software engineers and data scientists.

Graduate Research Assistant to Professor Michael Luca.

- Implemented weakly-supervised and human-in-the-loop machine learning algorithms to identify documents of interest in a litigation matter using natural language processing (NLP) techniques.- Developed and deployed dynamic application for data ingestion, sample selection, and visualization.

- Modeled high-resolution antitrust damages for more than 600,000 over-the-counter derivatives transactions.- Developed algorithm to validate and warehouse more than 10 million over-the-counter derivatives transactions associated with class-action antitrust claims.- Created and deployed algorithms to identify typos in millions of records of hand-entered data and impute values.- Assisted in modeling value of illiquid real estate investments and biotechnology firms.

Research Assistant to Professor Charles Holt in the field of Experimental Economics.